Presser Lance D, Baronti Cécile, Moegling Ramona, Pezzi Laura, Lustig Yaniv, Gossner Céline M, Reusken Chantal B E M, Charrel Rémi N
National Institute for Public Health and the Environment (RIVM), Center for Infectious Disease Control, Bilthoven, the Netherlands.
Unite des Virus Emergents (UVE: Aix-Marseille Univ, Universita di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
J Clin Microbiol. 2025 Jan 31;63(1):e0091024. doi: 10.1128/jcm.00910-24. Epub 2024 Dec 16.
Mosquito-borne viruses represent a large global health burden. With geographic expansion of competent vectors for chikungunya virus (CHIKV), dengue virus (DENV), and Zika virus (ZIKV) in Europe, it is anticipated that the number of autochthonous cases of these tropical viruses in Europe will increase. Therefore, regular assessment of diagnostic capabilities in Europe is important. Our aim was to evaluate the mosquito-borne virus molecular detection capability of expert European laboratories by conducting an external quality assessment in October 2023. Molecular panels included 12 plasma samples: one alphavirus (CHIKV), four orthoflaviviruses (ZIKV, yellow fever virus [YFV], DENV, and Japanese encephalitis virus [JEV]), and two negative control samples. Mosquito-borne virus detection was assessed among 36 laboratories in 24 European countries. Adequate capabilities were lacking for YFV and JEV. Many laboratories relied on a mix of laboratory-developed tests (some of which were pan-orthoflavivirus or pan-alphavirus in combination with sequencing) and commercial assays. 47.2% of laboratories characterized all external quality assessment (EQA) samples correctly. Correct result rates were 100% for CHIKV and ZIKV and >99% for DENV, but laboratories lacked capacity, specificity, and sensitivity for JEV and YFV. Three of the viruses in this panel emerged and transiently circulated in Europe: CHIKV, ZIKV, and DENV. Molecular detection was excellent for those viruses, but <50% is accurate for the remainder of the panel. With the possibility or continuation of imported cases and a growing global concern about climate change and vector expansion, progress toward rapid, accurate mosquito-borne virus diagnostics in Europe is recommended, as well as regular EQAs to monitor it.IMPORTANCEThe external quality assessment (EQA) focused on -borne viruses: chikungunya virus (CHIKV), dengue virus (DENV), Zika virus (ZIKV), and yellow fever virus (YFV). Japanese encephalitis virus, an orthoflavivirus that is spread by mosquito species belonging to the genus , was included in the quality assessment as well. CHIKV, DENV, and ZIKV have proven potential for transient and limited circulation in Europe upon introduction of viremic travelers returning to -endemic regions. Results of this EQA were excellent for those viruses, but <50% is accurate for the remainder of the panel (YFV and Japanese encephalitis virus). Considering imported cases and the threat of climate change and competent vector expansion, progress toward rapid, accurate mosquito-borne virus diagnostics in Europe is recommended.
蚊媒病毒给全球健康带来了巨大负担。随着基孔肯雅病毒(CHIKV)、登革病毒(DENV)和寨卡病毒(ZIKV)在欧洲的适宜传播媒介地理范围不断扩大,预计这些热带病毒在欧洲的本土病例数量将会增加。因此,定期评估欧洲的诊断能力很重要。我们的目标是通过在2023年10月开展一次外部质量评估,来评估欧洲专业实验室对蚊媒病毒的分子检测能力。分子检测样本组包括12份血浆样本:一种甲病毒(CHIKV)、四种正黄病毒(ZIKV、黄热病病毒[YFV]、DENV和日本脑炎病毒[JEV]),以及两份阴性对照样本。对24个欧洲国家的36个实验室进行了蚊媒病毒检测评估。对YFV和JEV缺乏足够的检测能力。许多实验室依赖于多种实验室自行开发的检测方法(其中一些是泛正黄病毒或泛甲病毒检测方法并结合测序)以及商业检测方法。47.2%的实验室正确鉴定了所有外部质量评估(EQA)样本。CHIKV和ZIKV的正确结果率为100%,DENV的正确结果率>99%,但实验室对JEV和YFV缺乏检测能力、特异性和灵敏度。该样本组中的三种病毒(CHIKV、ZIKV和DENV)在欧洲出现并短暂传播。对这些病毒的分子检测效果很好,但对样本组中的其他病毒(YFV和日本脑炎病毒)检测准确率<50%。鉴于存在输入病例的可能性或持续情况,以及全球对气候变化和传播媒介扩张的日益关注,建议欧洲在快速、准确诊断蚊媒病毒方面取得进展,并定期进行外部质量评估以监测进展情况。
外部质量评估(EQA)聚焦于蚊媒病毒:基孔肯雅病毒(CHIKV)、登革病毒(DENV)、寨卡病毒(ZIKV)和黄热病病毒(YFV)。作为质量评估的一部分,还纳入了日本脑炎病毒,这是一种通过库蚊属蚊虫传播的正黄病毒。CHIKV、DENV和ZIKV已被证明,当病毒血症患者返回流行地区后,有在欧洲短暂且有限传播的可能性。对这些病毒而言,此次外部质量评估的结果很好,但对样本组中的其他病毒(YFV和日本脑炎病毒)检测准确率<50%。考虑到输入病例以及气候变化和适宜传播媒介扩张的威胁,建议欧洲在快速、准确诊断蚊媒病毒方面取得进展。